Nasdaq: SGP · Listed Feb 6, 2026
SpyGlass Pharma IPO
IPO price
$16.00
SpyGlass Pharma (SGP) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 6, 2026.
SGP today$29.97+87.31%since IPO15-min delayed · as of 4:56:34 PM EST on Nov 18, 2026
See the SGP quoteFirst trading day · Feb 6, 2026
- IPO price
- $16.00
- inside the range of $15 to $17
- First trade
- $24.00
- +50.00% from the IPO price
- First-day last trade
- $26.80
- +67.50% from the IPO price, regular session
- Raise
- $150M
- before the underwriters' option
These numbers are from the first trading day, Feb 6, 2026.
How SGP did against the market
SGP against the market, from its first trade at 12:10 ET to the last trade of the session.
- SGP from its first trade
- +11.67%
- Against the market (QQQ)
- +11.3 pts
SGP rose 11.7% from its first trade to the last trade of the session. That is 11.3 points better than the market.
Same-day moves do not show that SGP caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
SGP against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
SGP against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| SpyGlass Pharma '26 | $150M | +50.00% | +67.50% | +72.59% | +62.81% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The SpyGlass Pharma IPO offers 9.38M shares to raise $150M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $16.00
- Shares offered
- 9.38M
- Money raised
- $150M
- Listing date
- Feb 6, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- SpyGlass Pharma$150M
Where SGP ranks
SpyGlass Pharma's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- SGP$993.14M
SGP news
The latest news and headlines about SpyGlass Pharma (SGP).
- SpyGlass Pharma Appoints Shannon Treviño as General CounselpositiveGlobeNewswire Inc.· Jun 15, 2026
Filings and the company
What SpyGlass Pharma has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that SpyGlass Pharma discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 11, 2026, SpyGlass Pharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Clinical trial resultsOct 19, 2026
On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System.
- Acquisition completionOct 1, 2026
At the closing under the Purchase Agreement, which occurred on October 1, 2026 (the "Closing"), the Company acquired 100% of the outstanding equity securities (the "Shares") of Advanced Vision Science, Inc., a California corporation ("AVS"), from Seller (the "Acquisition"). The aggregate consideration paid by the Company at the Closing for the Shares was based on a purchase price of $13,000,000, subject to customary adjustments.
- Clinical trial resultsMar 9, 2026
SpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial.
- Executive compensation changeFeb 13, 2026
On February 12, 2026, the Compensation Committee approved performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025, which will be paid shortly following such approval. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated 'Summary Compensation Table for Fiscal 2024 and 2025', which includes the amount of performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025 in the 'Non-Equity Incentive Plan Compensation' column.
About SpyGlass Pharma
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
- Ticker
- SGP
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Employees
- 65
- Listed
- Feb 6, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the SpyGlass Pharma IPO price?
$16.00 a share.
When did SpyGlass Pharma go public?
SpyGlass Pharma listed on Nasdaq on Feb 6, 2026 under the ticker SGP.
How much did the SpyGlass Pharma IPO raise?
$150M, before any underwriters' option.
How did SpyGlass Pharma open on its first day?
SGP first traded at $24.00, +50.00% from the IPO price of $16.00.
How did SGP close on its first day?
Its last regular-session trade was $26.80, +67.50% from the IPO price of $16.00.
What was the SGP first-day trading range?
$20.16 to $32.44 in the regular session.
How many SGP shares traded on the first day?
1.13M shares in the regular session.
How many shares did SpyGlass Pharma sell in its IPO?
9.38M shares.
How did SGP do against the market on its first day?
SGP rose 11.7% from its first trade to the last trade of the session. That is 11.3 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is SGP listed on?
SpyGlass Pharma lists on Nasdaq under the ticker SGP.
Build with Massive
Get the SGP data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/SGP/range/5/minute |
| Market cap | /v3/reference/tickers/SGP |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.